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2Summary
Oral tongue carcinoma is common, particularly in chronic smokers, drinkers and betal squid 
chewers. This is an aggressive tumor in which patients often present in late stage and have 
high recurrence rate after treatment. In this article, we report the first proteomic analysis of 
oral tongue carcinoma to globally search for the tumor-related proteins. Apart from helping 
us to understand the molecular pathogenesis of the tumor, these proteins may also have 
potential clinical applications as biomarkers in the surveillance of early cancers of high-risk 
persons, the treatment response prediction and the detection of residual or recurrent 
carcinoma after treatment. The protein expression profiles of ten oral tongue squamous cell 
carcinomas and their matched normal mucosal resection margins were examined by 2D gel 
electrophoresis and MALDI-TOF mass spectroscopy. A number of tumor-associated proteins 
including HSP60, HSP27,  B-crystalline, ATP synthase , calgranulin B, myosin, 
tropomyosin and galectin 1 have been found consistently and significantly altered in their 
expression levels in tongue carcinoma tissues, compared with their paired normal mucosae. 
The expression profile portrays a global protein alteration that appears specific to the oral 
tongue cancer. The potential of utilizing these tumor-related proteins for screening cancer and 
monitoring recurrence warrants further investigation.
31 Introduction
Upper aerodigestive tract carcinoma (UADTSCC) is a major public health problem 
worldwide. Oral tongue carcinoma is one of the common UADTSCC. The genetic 
pathogenesis is still largely unclear. The clinical diagnostic methods mainly rely on
symptoms presentation, physical signs and X-ray examination. Unfortunately, the majority of 
patients were in the advanced stage at the time of first symptomatic presentation and clinical 
diagnosis [1-6]. The recurrence rate after treatment increases with stage. For those patients 
with recurrent carcinoma, further salvage treatment is successful only when the tumors are 
detected in the early stage. All patients who were not feasible for surgical salvage died of 
recurrence despite of giving chemotherapy and/or radiotherapy [7, 8]. With the present 
clinical assessment method, half of the patients are not salvageable at the time of diagnosis of 
recurrence and another quarter of patients fail to respond to the salvage treatment because of 
the advanced stage of recurrence. Obviously, a better method for screening UADTSCC and 
an early detection of residual or recurrent tumor after treatment are necessary to improve the 
curative rate.
Proteomics is a powerful analytic technology newly developed to enhance our study 
on the diagnosis, treatment and prevention of human diseases [9-11]. Two-dimensional (2D) 
gel electrophoresis has been the principal tool in proteomics, which is able to resolve 
thousands of proteins in one experiment, providing the highest resolution in protein 
separation. By comprehensively examining the expression profiles of proteins between 
normal and diseased samples via 2D electrophoresis, proteomics can produce information on 
new biomarkers, disease-associated targets and the process of pathogenesis. This technique 
has been extensively employed to investigate various diseases [12-15] but there is currently 
no report concerning the proteomic study on UADTSCC. In this study, we used 2D 
electrophoresis to analyze protein samples extracted from oral tongue tumor tissue and 
4matched surrounding histologically normal mucosa from surgical specimens. By carefully 
selecting carcinoma confining to one subsite of the upper aerodigestive tract and patients 
without any prior radiotherapy and chemotherapy treatment to the tissue, we hope to reduce 
the tissue variability, avoid treatment-induced effect on protein expression and yield more 
consistent results. By comparing the protein profiles between tumor and normal samples, we 
report herein the identification of proteins that were differentially expressed in tumor. Further 
global characterization of these proteins provides information for better understanding the 
pathogenesis of tongue cancer and thus help developing new diagnostic and therapeutic 
strategies.
52 Materials and methods
2.1 Tissue and sample preparation 
Ten pairs of surgical specimens of primary oral tongue sqaumous cell carcinoma and their 
matched adjacent normal mucosae were collected from Queen Mary Hospital, the University 
of Hong Kong, and were stored in deep freezer (–80oC) until use. The study has been 
approved by ethnic committee. All patients have sent a consent form to donate tissue and 
blood for research purpose. There were 5 male and 5 female patients ranging from 29 to 81 
year old. The AJCC pathologic stages were 1 T1N0 M0, 7 T2(6N0, 1N2)M0, 2 T3(1N0, 
1N2)M0. Table 1 lists detailed histological data for the tissue samples used and Figure 1 is a 
representative histological picture showing a pair of matched tissue samples side by side. 
Overall, the tumor specimens contain 64 ± 22 % tumor cells.
Tissues (~200 mg) were cut into about 2 mm3 in size and were then homogenized 
with 0.5 ml Lysis Buffer (Reagent 3, Bio-Rad, containing protease inhibitor cocktail, Sigma 
8340, DNase I 1 Uunit/ml) for 5 min on ice using a mini-homogenizer. The lysate was spun 
down at 14,000 rpm for 10 minutes at 4oC, the supernatant was transferred into another tube, 
and then ultra-centrifuged at 100,000 g for 1 hour at 4oC. The protein concentration of the 
resulting supernatants was determined by the method of Bradford and the protein samples 
were stored at –80oC in aliquot. 
2.2 2D-gel electrophoresis 
The 2D-gel electrophoresis was carried out with Amersham Biosystems IPGphor IEF and 
Ettan Dalt six electrophoresis units by following the protocol described previously [16]. 
Protein samples (150 ~ 200 µg) extracted from tumor center (TC) and surrounding 
histologically normal mucosa (SM) were applied to the 2D gel electrophoresis and run in pair 
6side by side. Triplicate electrophoresis was performed for each pair sample to ensure the 
reproducibility. All gels were visualized by silver staining [16].
2.3 Image analysis and MS peptide sequencing
Image acquisition and analysis were performed by using an ImageScanner (Amersham) and 
the ImageMaster 2D Elite software (Amersham) [16]. Comparison was made between gel 
images of TC and SM samples pair by pair. Normalized volume differences were statistically 
calculated for all the ten cases. Those consistently and significantly different spots were 
selected for analysis with MALDI-TOF mass spectrometry. Protein spots were cut out in 
small pieces and subjected to in-gel tryptic digestion overnight [16]. Peptide mass spectra 
were recorded and parameters for spectra acquisition were used as stated previously [16]. In 
database protein matching using MS-Fit (http://prospector.ucsf.edu/), 20 ppm or better mass 
accuracy and MOWSE scores over 200 were obtained in most of analysis. For those lower 
mass accuracy and score matching, duplicate or triplicate run and analysis were carried out to 
ensure the accuracy. 
73 Results
3.1 Sample preparation and protein separation. 
Before applied to 2D-gel separation, proteins were extracted from tissue samples and
subjected to concentration determination. Total protein extraction rates have no significant 
difference between tumor and matched surrounding tissues, with 31.7 ± 8.5 and 30.3 ± 7.5 
µg/mg respectively for TC and SM samples. Usually 200 µg of proteins each sample were 
used for 2D-gel separation and the proteins were quite evenly distributed in the 18 cm gel 
with ranges of pI 4-10 and MW 6-200kDa. Figure 2 is the typical master gel image for both 
TC and SM samples side by side. Around 600 protein spots in each gel were detected through 
ImageMaster software. Some proteins present in train spots, indicating that modified proteins 
or isoforms were fairly separated by the 2D-gel electrophoresis. Highlighted in squares are 
the eight areas showing consistent and significant differences at least in nine of the ten cases. 
Statistic data for these proteins (or the sum of isoforms) were summarized in Table 2 with 
total normalized volumes (% Vol) and fold differences between TC and SM samples (for 
total ten pairs).  Roughly, nine proteins (or isoforms) are up-regulated and six proteins 
(isoforms) are suppressed significantly in tumor tissues. 
3.2 Protein identification.  
Each different protein spot was excised and subjected to in-gel tryptic digestion, MALDI-
TOF mass measurement and database matching. Isoforms that gave an identical primary 
structure in the protein matching are classified into one protein. Table 3 is the summary for 
the protein identification, most of the protein matching have high sequence coverage, mass 
accuracy and MOWSE score. 
Figure 3 & 4 show the alterations of expression levels for each identified protein 
between tumor and normal mucosae. Myosin heavy chain 1 (MHC1) and galectin 1 are 
8evidently increased (+5, and +1.5 folds, respectively) in tumor tissue, whereas myosin light 
chains (MLC) are dramatically down-regulated (5.7 to –11 folds) (Fig. 3 I & V). MLC has 
three groups respectively belong to light chain 1, alkali light chain and regulatory light chain 
from high to lower MW in the gel. In some cases, all the three MLC groups were suppressed 
to an undetectable level in tumor center tissues. Interestingly, tropomyosin has alterations 
similar to myosin in expression level. Tropomyosin  chain was significantly decreased (4.5 
folds) and its lower MW isoform was remarkably increased (+6.1 folds) in tumor (Fig. 3 III). 
Compared to those in normal mucosa, other proteins consistently showing apparent 
increase in expression level in tumor samples include heat shock 60k protein (HSP60) (+2 
folds), heat shock 27k protein (HSP27) (+1.5 folds), nuclear FMRP interacting protein 1
(+1.7 folds), calgranulin B (+1.5 folds) and hemoglobin (+2.1 folds), while proteins 
considerably suppressed in tumor are ATP synthase  chain (2.3 folds) and crystalline B 
(2.9 folds) (Fig. 4). It should be pointed out that almost all these proteins and isoforms have 
molecular weights matching to their experimental values in gels. The only exception is 
nuclear FMRP interacting protein 1; it has 31.3 kDa in size, the spot that appeared in 15 kDa 
region obviously is a fragment of the protein. The matched peptides (all in the beginning part 
of the protein sequence) and sequence coverage in the protein matching justify the 
assignment.
94 Discussion
Oral tongue squamous cell carcinoma originates from the mucosa layer. Tongue consists 
largely of skeletal muscle covered by a thin layer of mucosa and submucosa. Pathologic 
feature of muscular invasion is therefore present in most tongue cancer starting from early 
stage. Muscular invasion was observed in all tumor specimens in this study. Myosin is the 
structural component of the muscle cytoskeleton. Myosin modulation participates in the 
process of epithelial cancer progression [17, 18]. In ras transformed fibroblast cells [19] and 
muscle cells treated with tumor necrosis factor- [20] and cancer cachexia [21], both MHC 
and MLC were significantly suppressed. Our finding of the dramatic decline in MLC 
expression level in tongue tumor tissue reflects the muscle destruction during cancer invasion 
and migration process. What surprised us is the fact that, despite of the reduction of MLC, 
there was substantially increased level of MHC (isoform 1) consistently found in tumor 
tissue. This unexpected finding has not been previously reported in other cancers, and thus 
may suggest a pathologic phenomenon specific to oral tongue cancer muscular invasion 
process. Further study is necessary to elucidate the underlying molecular pathogenesis.    
Tropomyosin is a cytoskeletal microfilament binding protein expressed in muscle and 
non-muscle cells. There are several tropomyosin isoforms, and their expression is known to 
be associated with cell transformation events. Suppression of high MW isoforms of muscle 
tropomyosin was commonly observed in malignant tumors such as breast, ovarian and 
prostate cancer [22]. Interestingly, we found in this study that, accompanying with a 
substantial suppression of the higher MW tropomyosin , a low MW tropomyosin isoform 
was siginificantly over-expressed in tongue tumor tissue (Table 2). This may indicate that 
different tropomyosin isoforms perform distinct physiological functions in tissue, resulting in 
diverse regulation in malignant cells [23-26]. In addition, earlier studies revealed that 
increased expression of a low MW tropomyosin isoform was correlated to the metastatic 
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potential of other tumors such as primary breast carcinoma [27], melanoma [28] and Lewis 
lung carcinoma [29], a similar finding in this study suggests that the correlation between 
tropomyosin and metastasis may also play a role in oral tongue cancer.  
Another muscle-related protein with altered expression level in tongue tumor is 
galectin 1. Galectin 1, together with galectin 3, belongs to a family of -galactoside-binding 
animal lectins, which are involved in cell differentiation, morphogenesis, tumor progression 
and metastasis. Extensive investigation has shown that up-regulation of galectin 1 & 3 were 
found in various carcinomas including colon cancer [30], prostate cancer [31], intrahepatic 
cholangiocarcinoma [32], bladder transitional-cell carcinoma [33], and head and neck tumors 
[34-36]. The observed elevated expression of galectin 1 in this report implicates that tongue 
SCC tumor may share the similar mechanism of malignant progression mediated by galectin 
in promoting cancer cell invasion and migration. It has been suggested that galectin 
modulates cell adhesion, regulates cell growth, inhibits apoptosis, and therefore enhances the 
migratory capabilities of tumor astrocytes and their biological aggressiveness [37-39].  
HSP60, HSP27 and alpha B-crystallin are a group of stress-related proteins which 
expression was considerably altered in tumor tissues. Heat-shock proteins are synthesized by 
cells in response to heat and other environmental stress. Their expression in cells may have 
important physiological and pathological implications such as protection, cell proliferation, 
migration and differentiation and disease prognosis. However, numerous research data from 
different laboratories indicated that these three HSP proteins were modulated independently 
in response to stress [22, 40-43]. While the expression of HSP60 and HSP27 was stimulated 
[22, 44-46], alpha B-crystallin was suppressed [40-43, 47] in various tumors. The current 
observations on the expression of this group of HSP proteins in tongue tumor (Table 2) are 
exactly consistent with the published results from studies on other cancers. This confirms that 
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the small heat shock protein, alpha B-crystallin, may play a distinctive role in the process of 
carcinogenesis although it shares structural and functional properties with HSP27.   
Calgranulin B, also called S100A9 and MRP14, is a member of S100 calcium-binding
protein family predominantly expressed in granulocytes. Its biological functions include the 
intracellular inhibition of casein kinase II which results in the regulation of cellular 
transcription and translation and the extracellular chemotactic and cytotoxic activity against 
bacteria, fungi and tumor cells [48]. Calgranulin B over-expression has been found in colon 
and colorectal cancers [49-51] and this protein has been identified to be tumor-associated 
protein [52-54]. The higher expression of calgranulin B in TC samples in this study confirms 
that this tumor marker is also positively up-regulated in oral tongue cancer. However, 
previous study using a cDNA array hybridization method revealed that the cDNA level of 
calgranulin B was much higher in non-malignant cells than that in tumor cells of 
nasopharyngeal carcinoma [55]. The reasonable explanation would be that cDNA level may 
not necessarily reflect protein expression level and the protein expression differs in different 
tissue types. 
ATP synthase  chain, the catalytic subunit in the ATP synthase complex, was found 
being markedly down-regulated in tumor tissue (Table 2). This seems contradictory to the 
fact that tumor cell growth needs a lot of energy from ATP synthesized by ATP synthase.  
However, recent studies showed that, while ATP synthase D and E chains increased their 
expression in lung, liver and thyroid tumors [56-59], ATP synthase  in fact decreased its 
content in hepatocellular carcinoma [60, 61]. The reduction of ATP synthase  was 
subsequently found to be related to the over-expression of an ATPase inhibitor protein in 
tumor, which prevents hydrolysis of glycolytic ATP, declines the activity of the ATP 
synthase and therefore modulates the expression of ATP synthase  [60]. The process of oral 
tongue SCC may share the similar mechanism in this respect.
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The last two proteins that had higher expression levels in tumor samples are nuclear 
FMRP interacting protein and hemoglobin. The nuclear FMRP interacting protein is a newly 
discovered RNA-binding protein that interacts with the fragile X mental retardation protein 
(FMRP) responsible for the fragile X syndrome through its silenced expression [62, 63]. 
There is currently no report concerning the expression of the FMRP interacting protein in 
tumors. The reason for the up-regulation of this protein in tongue cancer is unclear. On the 
other hand, the relationship between tissue hemoglobin level and tongue SCC tumor appears 
indirect. Angiogenesis is one of the important factor to promote tumor growth. Angiogenesis 
in oral tongue carcinoma is an unfavorable prognostic factor [64-66]. The higher hemoglobin 
level in tumor tissues compared with normal mucosa is consistent with the higher vascular 
density of growing tumor in normal tissues. 
In summary, we have used proteomic technology to globally analyze tongue SCC 
cancer for the first time. The elicited identification of tumor-associated proteins, including 
myosin, tropomyosin, galectin 1, HSP60, HSP27,  B-crystalline, ATP synthase  and 
calgranulin B, and the alterations of these proteins in expression level help us better 
understand the carcinogenesis of oral tongue cancer. These proteins individually may not be 
specific to tongue SCC cancer, however, a combinational evaluation integrated with the 
functions and quantitative changes of these proteins holds a potential to be a unique index for 
assessing the disease. It is therefore worthwhile to further study the plasma levels of these 
protein biomarkers for their clinical application in screening cancer and monitoring 
recurrence after treatment. This possibility is under investigation.  
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Table 1. Patients’ information and histological data for the tissue samples used.
PATIENTS SEX/AGE T STAGE SAMPLE 
PAIRS
TUMOR
CELLS (%)
NORMAL
MUCOSAL
CELLS (%)
MUSCLE
CELLS (%)
CONNECTIVE TISSUE CELLS
LYMPHOCYTES, VESSEL CELLS, 
FIBROBLAST (%)
1 F/29 T2 Tumor (TC)
Mucosa (SM)
65
0
0
100
15
0
20
0
2 M/70 T2 Tumor (TC)
Mucosa (SM)
60
0
0
30
30
20
10
50
3 F/62 T2 Tumor (TC)
Mucosa (SM)
60
0
0
20
5
60
35
20
4 M/53 T3 Tumor (TC)
Mucosa (SM)
90
0
0
25
0
20
10
55
5 M/59 T3 Tumor (TC)
Mucosa (SM)
90
0
0
40
0
20
10
40
6 M/50 T2 Tumor (TC)
Mucosa (SM)
35
0
0
30
60
60
5
10
7 F/81 T2 Tumor (TC)
Mucosa (SM)
50
0
0
20
5
70
45
10
8 M/69 T2 Tumor (TC)
Mucosa (SM)
90
0
0
95
0
0
10
5
9 F/70 T1 Tumor (TC)
Mucosa (SM)
25
0
0
40
50
20
25
40
10 F/59 T2 Tumor (TC)
Mucosa (SM)
70
0
0
40
20
20
10
40
* Relative percentage (%) of cells was round up to 5%, cells less than 5% were counted as 0 as the number was too small.
19
Table 2: Summary of protein alterations 
PROTEIN ID AREA EXPERIMENTAL
MW/PI
TC (% VOL) SM (% VOL) FOLD 
DIFFERENCE
Myosin heavy chain SM1 I 200kD/7.5pI 0.997 ± 0.577 0.200 ± 0.104 +5
Heat shock 60kD protein 1 II 65kD/5.2-5.5pI 0.320 ± 0.203 0.162 ± 0.144 +2
ATP synthase  chain II 56kD/5.0-5.4pI 0.372 ± 0.329 0.840 ± 0.563 –2.3
Tropomyosin  chain III 39-43kD/4.9pI 0.601 ± 0.312 2.687 ± 1.088 -4.5
Tropomyosin isoform III 36kD/4.9pI 0.546 ± 0.327 0.090 ± 0.055 +6.1
Heat shock protein 27 IV 30kD/5.8-6.5pI 1.153 ± 0.397 0.790 ± 0.260 +1.5
Myosin light chain 1 V 25kD/4.7-5.1pI 0.604 ± 0.509 3.456 ± 0.862 –5.7
Myosin alkali light chain 1 V 13-14kD/4.6pI 0.238 ± 0.372 1.543 ± 0.617 –6.5
Myosin regulatory light chain 2 V 16-20kD/4.6-5.1pI 0.316 ± 0.242 3.439 ± 1.449 –11
Galectin 1 V 12-13kD/4.9-5.3pI 1.981 ± 0.971 1.308 ± 0.289 +1.5
Crystallin  B (HSP20 like-protein) VI 22-23kD/6.7-7.3pI 0.345 ± 0.362 0.994 ± 0.328 –2.9
Nuclear FMRP interacting protein 1 VII 15kD/6.3pI 1.096 ± 0.366 0.647 ± 0.319 +1.7
Calgranulin B VII 14kD/5.5pI 0.774 ± 0.398 0.546 ± 0.140 +1.5
Hemoglobin VIII 15.9kD/8.2pI 6.336 ± 4.259 3.041 ± 2.068 +2.1
* SM: Surrounding mucosa; TC: Tumor center.
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Table 3. Results of MALDI-TOF mass spectra and database searching for protein 
identification. 
PROTEIN ID PEPTIDES 
MATCHED
SEQUENCE 
COVERAGE
MASS 
ACCURACY
MOWSE 
SCORE
Myosin heavy chain SM1 24 16% 41 ppm 3528
HSP60 (chaperonin) 5 12% 20 ppm 241
ATP synthase  chain 13 31% 6 ppm 20830
Tropomyosin  chain 14 46% 25 ppm 771
Tropomyosin isoform 18 47% 10 ppm 2121
Heat shock protein 27 11 59% 12 ppm 3207
Myosin light chain 1 10 51 % 11 ppm 3527
Myosin alkali light chain 10 45% 13 ppm 3920
Myosin regulatory light 
chain 2
7 42% 5 ppm 213
Galectin 1 5 41 % 17 ppm 41
Nuclear FMRP interacting 
protein 1
5 13 % 8 ppm 23
Calgranulin B 11 84% 13 ppm 1122
Crystallin  B (HSP20 like-
protein)
13 51% 20 ppm 3770
Hemoglobin  chain 11 77 % 14 ppm 1126
Hemoglobin  chain 6 74 % 10 ppm 4817
* SM: Surrounding mucosa; TC: Tumor center.
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Figure Legends
Figure 1. Representative histological picture showing a pair of matched tissue specimens 
side by side.
Figure 2. Representative master 2D-gel images of tumor center and surrounding mucosa 
samples. Highlighted in squares are the eight areas showing significant and consistent 
differences in protein expression level. 
Figure 3. Patterns of protein alterations in Area I, III and V. MHC & MLC: myosin heavy 
and light chains.
Figure 4. Protein alterations in Areas II, IV, VI, VII and VIII. 
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Figure 1
Normal tongue mucosa Tongue tumor center
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